Study of PF-07248144 in Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

February 3, 2028

Study Completion Date

September 22, 2029

Conditions
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
DRUG

PF-07248144

KAT6 Inhibitor

DRUG

Fulvestrant

Endocrine Therapy

DRUG

Letrozole

Endocrine Therapy

DRUG

Palbociclib

CDK4/6 Inhibitor

DRUG

PF-07220060

CDK4 inhibitor

DRUG

PF-07850327, ARV-471, vepdegestrant

PROTAC (PROteolysis Targeting Chimera) ER degrader

Trial Locations (41)

2050

TERMINATED

Chris O'Brien Lifehouse, Camperdown

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

3021

RECRUITING

Western Health-Sunshine & Footscray Hospitals, St Albans

3050

RECRUITING

Royal Melbourne Hospital, Parkville

5000

RECRUITING

Cancer Research South Australia, Adelaide

6008

RECRUITING

St. John of God Subiaco Hospital, Subiaco

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam

33308

TERMINATED

Holy Cross Hospital, Fort Lauderdale

37067

RECRUITING

Tennessee Oncology PLLC, Franklin

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

RECRUITING

Tennessee Oncology PLLC, Nashville

RECRUITING

The Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville

40202

RECRUITING

James Graham Brown Cancer Center, Louisville

RECRUITING

University Medical Center, lnc.:DBA University of Louisville Hospital, Louisville

41017

RECRUITING

St. Elizabeth Healthcare, Edgewood

41404

RECRUITING

Kyungpook National University Chilgok Hospital, Daegu

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

RECRUITING

U.T. MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

85258

TERMINATED

HonorHealth, Scottsdale

90048

RECRUITING

Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles

RECRUITING

Cedars-Sinai Medical Center; SOCCI Pharmacy, Los Angeles

94158

RECRUITING

UCSF Medical Center at Mission Bay, San Francisco

98104

RECRUITING

Swedish Cancer Institute, Seattle

98122

RECRUITING

Swedish Medical Center, Seattle

100142

RECRUITING

Beijing Cancer hospital, Beijing

132000

RECRUITING

Jilin Province Tumor Hospital, Changchun

430079

NOT_YET_RECRUITING

Hubei Cancer Hospital, Wuhan

510060

RECRUITING

SUN Yat-Sen University Cancer Center, Guangzhou

710061

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

2418515

RECRUITING

Kanagawa cancer center, Yokohama

06510

RECRUITING

Smilow Cancer Hospital at Yale - New Haven, New Haven

RECRUITING

Yale-New Haven Hospital- Yale Cancer Center, New Haven

06511

RECRUITING

Smilow Cancer Hospital Phase 1 Unit, New Haven

464-8681

RECRUITING

Aichi Cancer Center Hospital, Nagoya

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

104-0045

RECRUITING

National Cancer Center Hospital, Chuo-ku

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04606446 - Study of PF-07248144 in Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter